Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.69 |
| ▸ | CTSK | P43235 | 6/20 | 0.69 |
| ▸ | REN | P00797 | 3/20 | 0.61 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821431 | 1.00 | CTSS (0.69) | CTSSCTSKRENCTSBCTSL | |
| SCHEMBL8182259 | 1.00 | CTSS (0.69) | CTSSCTSKRENCTSBCTSL | |
| SCHEMBL4420859 | 0.93 | REN (0.67) | CTSSCTSKRENCTSBCTSL | |
| SCHEMBL7618822 | 0.93 | REN (0.67) | CTSSCTSKRENCTSBCTSL | |
| SCHEMBL2173588 | 0.93 | REN (0.67) | CTSSCTSKRENCTSBCTSL | |
| SCHEMBL18235374 | 0.91 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1326276 | 0.89 | CTSS (0.72) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1325181 | 0.89 | CTSS (0.72) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1325182 | 0.89 | CTSS (0.72) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL2714740 | 0.89 | CTSS (0.56) | CTSSCTSKRENCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | GENENTECH, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2022103411-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | GENENTECH, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | VHL, HIF1AN, EGLN2 | CTSS 3614/4885CTSK 3446/4885REN 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.